• Status: Closed

  • Key features: The Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network.

  • Programme: SBRI

  • Award: Up to £10 million

  • Opens: 29 Feb 2016, 00:00

  • Registration closes: 27 Apr 2016, 12:00

  • Closes: 04 May 2016, 12:00

  • Support phone number: 0300 321 4357

« go back

New vaccines for global epidemics: development and manufacture

Summary

Department of Health logoThe Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network.
 
This SBRI competition aims to stimulate the development of:
  • vaccine for priority infectious diseases
  • vaccine platform technology
  • manufacturing technologies that would allow for the rapid manufacture of vaccines in low-income settings
The competition will be in 2 streams.
 
In stream 1 up to £6 million is available for exploring scientific and technical feasibility. This stream is mainly aimed at the development of vaccines and vaccine technology
that is still some way from being ready to be used in phase I human trials. Individual contracts will be for up to £500,000, to be spent within 12 months of contract award. Depending on the success of projects from this stream, the Department of Health will consider further major awards to progress product development.
 
In stream 2 up to £4 million is available to projects at a more advanced stage of development. This stream is mainly aimed at candidate vaccines that are now, or will soon be, ready for phase I human trials and manufacturing technology that could potentially be commercially viable in the near future. Individual contracts for this stream will be for £500,000 to £1 million, to be spent within 18 months of contract award. Projects with higher or lower costs will also be considered on a case-by-case basis.
 
The competition is open to all organisations that can demonstrate that their product or work has a realistic route to market, whether in the short or long term. Successful organisations will attract a 100% funded development contract.
 
This competition is wholly funded by Official Development Assistance (ODA). This means that while work on projects can be carried out in high-income countries, there must be a clear explanation of how the research/project will benefit those in low-income countries.
 
The Department of Health recognises that there is no time to lose in the development of candidate vaccines, vaccine platform technology and vaccine manufacturing technology to combat priority infectious diseases. As such, there is particular interest in projects that can begin rapidly and have the potential to spend significant amounts of the contract award in calendar year 2016.
 
The competition opens on 29 February 2016. The deadline for registration is at noon on 27 April 2016, and the deadline for applications is at noon on 4 May 2016. Listen to a recording of the event briefing from the 11 March 2016 .

Scope

This competition will support projects seeking to develop vaccines, vaccine platform technologies and manufacturing technologies that will enable an effective, rapid response during future outbreaks of the following pathogens: Chikungunya, Crimean-Congo Haemorrhagic Fever, Dengue Virus, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika.

Out of scope

In this competition we are not funding projects covering:
  • new agents/technologies not related to the diseases listed above
  • discovery of wholly new immunisation agents
  • development of agents for animal disease that cannot demonstrate a clear impact on human health

For full details on the scope of this competition, see the competition brief.

Key dates

Competition opens 29 February 2016
Briefing event 11 March 2016
Registration deadline 27 April 2016 noon
Deadline for applications 4 May 2016 noon
Contracts awarded September 2016

 

Supporting documents & links